SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

SABCS Expert Commentary |Professor Jin Feng: Deep Learning Accurately Predicts Late Distant Metastasis in HR-Positive Early Breast Cancer and Guides Decisions on Extended Endocrine Therapy

2026.01.13
At the 2025 San Antonio Breast Cancer Symposium (SABCS 2025), a study based on data from the NSABP B-42 and TAILORx trials (Abstract No. RF3-07) reported the development and validation of a multimodal, multitask deep learning model (Clarity BCR). By integrating routine digital pathology images with key clinical variables, this model accurately predicts the risk of late distant recurrence (late DR) in patients with hormone receptor–positive (HR+) early breast cancer and effectively identifies those who may benefit from extended endocrine therapy (EET).
Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

Professor Stephen J. Freedland: The EMBARK Study Opens a New Chapter of Intensified Therapy for High-Risk BCR Prostate Cancer

2026.01.12
In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier – UroStream invited Professor Stephen J. Freedland from Cedars-Sinai Medical Center to provide an in-depth interpretation of the EMBARK study, including its study rationale, clinical benefits, and individualized treatment strategies for high-risk BCR patients.
Voice of China at ASH |Professor Wang Hui / Wang Dongchu: From MRD Monitoring to Early CRS Identification—Unlocking New Paradigms in Immunologic Diagnosis and Therapy

Voice of China at ASH |Professor Wang Hui / Wang Dongchu: From MRD Monitoring to Early CRS Identification—Unlocking New Paradigms in Immunologic Diagnosis and Therapy

2026.01.11
From December 6 to 10, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. The meeting highlighted the latest advances in both clinical hematology and basic research, driving progress in the diagnosis and treatment of hematologic diseases as well as translational research.In this issue, we feature the research achievements of Professor Wang Hui’s team, covering cutting-edge technologies such as 16-color full-spectrum flow cytometry, a weighted cytokine scoring system, and other innovative approaches. These studies provide solid scientific evidence for early precise diagnosis, treatment response assessment, and timely clinical intervention, demonstrating the critical role of technological innovation in modern hematology. We warmly invite readers to engage in further discussion and exchange.
Individualized Treatment of Prostate Cancer and Clinical Management of NHT-Related Adverse Effects

Individualized Treatment of Prostate Cancer and Clinical Management of NHT-Related Adverse Effects

2026.01.10
In the era of precision medicine for prostate cancer, individualized clinical decision-making has become a central focus of daily practice. At a recent academic conference on urologic oncology, Professor Hailiang Zhang from Huadong Hospital affiliated with Fudan University shared his clinical perspectives on novel hormonal therapy (NHT) in metastatic prostate cancer. He emphasized that, based on solid evidence from randomized clinical trials, NHT combined with androgen deprivation therapy (ADT) has become the standard first-line treatment for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Nevertheless, optimal treatment selection requires an integrated assessment of tumor burden, genomic characteristics, patient age, and comorbidities, enabling a truly “tailor-made” approach.
Lymphoma Roundtable · ASH Special | Professor Cai Qingqing: New Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma

Lymphoma Roundtable · ASH Special | Professor Cai Qingqing: New Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma

2026.01.08
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded successfully in Orlando, USA. As the “grand finale” of the hematology field each year, this meeting showcased a series of cutting-edge breakthroughs in lymphoma research, providing new directions for optimizing clinical practice.
Breaking Diagnostic Bottlenecks: The IBMDX Study Reveals 37% Diagnostic Yield and Health Economic Value of Whole Genome Sequencing (WGS) in Inherited Bone Marrow Failure Syndromes

Breaking Diagnostic Bottlenecks: The IBMDX Study Reveals 37% Diagnostic Yield and Health Economic Value of Whole Genome Sequencing (WGS) in Inherited Bone Marrow Failure Syndromes

2025.12.30
At the 2025 American Society of Hematology (ASH) Annual Meeting, Dr. Lucy Fox from the Peter MacCallum Cancer Centre (Australia) presented the highly anticipated results of the IBMDX study. This landmark trial evaluated the clinical utility and economic impact of "Upfront Whole Genome Sequencing (WGS)" in patients with suspected Inherited Bone Marrow Failure Syndromes (IBMFS). The findings suggest a paradigm shift is underway: WGS not only achieves a diagnostic yield of 37%—surpassing traditional panels and exome sequencing—but also uncovers complex genomic mechanisms previously invisible to standard testing.